Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on 24-hour blood and ocular perfusion pressures: the results of a randomized trial

Luca Rossetti, Matteo Sacchi, Costas H Karabatsas, Fotis Topouzis, Michele Vetrugno, Marco Centofanti, Andreas Boehm, Christian Vorwerk, David Goldblum, Paolo Fogagnolo, Luca Rossetti, Matteo Sacchi, Costas H Karabatsas, Fotis Topouzis, Michele Vetrugno, Marco Centofanti, Andreas Boehm, Christian Vorwerk, David Goldblum, Paolo Fogagnolo

Abstract

Background: To compare the effect of bimatoprost and the fixed combination latanoprost-timolol (LTFC) on 24-hour systolic (SBP) and diastolic (DBP) blood pressure and on 24-hour ocular perfusion pressure (OPP).

Methods: 200 patients with glaucoma or ocular hypertension, controlled on the unfixed combination of latanoprost and timolol or eligible for dual therapy being not being fully controlled on monotherapy were enrolled in a randomized, double-masked, placebo-controlled, multicentre clinical trial. They were randomized to LTFC (8 a.m.) or bimatoprost (8 p.m.) and received 24-hour IOP curve at baseline, 6 and 12 weeks (supine and sitting position IOPs were recorded at 8 p.m., midnight, 5 a.m., 8a.m., noon and 4 p.m.). Holter 24-hour blood pressure curve was obtained between weeks 2 and 12. SBP, DBP, OPP were calculated and compared with ANOVA. Rates of diastolic OPP (DPP)≤50, ≤40, ≤30 mmHg in the 2 groups were calculated and compared using Fisher's test.

Results: Mean baseline SBP and DBP were 136.5±18.3 vs 134.2±20.1 mmHg (p=0.1) and 79.1±10.2 vs 78.2±10.1 mmHg (p=0.4) in the bimatoprost and LTFC groups respectively. Holter SBP was significantly higher for bimatoprost (135.1 mmHg vs 128.1 mmHg, p=0.04), while no statistically significant difference in DBP was found. DPP was similar in the 2 groups, and proportions of patients with at least one value of the 24-hour curve≤50, ≤40, ≤30 mmHg were 94%, 86%, 41% respectively.

Conclusions: Bimatoprost and LTFC had similar DBPs and OPPs; SBP was significantly lower with LTFC. In this study, the percentage of "dippers" was considerably higher than the one described in previous studies on the role of perfusion pressure in glaucoma.

Trial registration: NCT02154217, May 21, 2014.

Figures

Figure 1
Figure 1
Percentage of patients showing at least 1 DPP below the given cut-off values.

References

    1. Casson RJ, Chidlow G, Wood JP, Crowston JG, Goldberg I. Definition of glaucoma: clinical and experimental concepts. Clin Exp Ophthalmol. 2012;40:341–9. doi: 10.1111/j.1442-9071.2012.02773.x.
    1. De Moraes CG, Demirel S, Gardiner SK, Liebmann JM, Cioffi GA, Ritch R, et al. Effect of treatment on the rate of visual field change in the ocular hypertension treatment study observation group. Invest Ophthalmol Vis Sci. 2012;53:1704–9. doi: 10.1167/iovs.11-8186.
    1. Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z, et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114:1965–72. doi: 10.1016/j.ophtha.2007.03.016.
    1. Maier PC, Funk J, Schwarzer G, Antes G, Falck-Ytter YT. Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ. 2005;331(7509):134. doi: 10.1136/bmj.38506.594977.E0.
    1. Zheng Y, Wong TY, Mitchell P, Friedman DS, He M, Aung T. Distribution of ocular perfusion pressure and its relationship with open-angle glaucoma: the singapore malay eye study. Invest Ophthalmol Vis Sci. 2010;51:3399–404. doi: 10.1167/iovs.09-4867.
    1. Memarzadeh F, Ying-Lai M, Chung J, Azen SP, Varma R, Los Angeles Latino Eye Study Group Blood pressure, perfusion pressure, and open-angle glaucoma: the Los Angeles Latino Eye Study. Invest Ophthalmol Vis Sci. 2010;51:2872–7. doi: 10.1167/iovs.08-2956.
    1. Leske MC. Ocular perfusion pressure and glaucoma: clinical trial and epidemiologic findings. Curr Opin Ophthalmol. 2009;20:73–8. doi: 10.1097/ICU.0b013e32831eef82.
    1. Hulsman CA, Vingerling JR, Hofman A, Witteman JC, de Jong PT. Blood pressure, arterial stiffness, and open-angle glaucoma: the Rotterdam study. Arch Ophthalmol. 2007;125:805–12. doi: 10.1001/archopht.125.6.805.
    1. Bonomi L, Marchini G, Marraffa M, Bernardi P, Morbio R, Varotto A. Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. Ophthalmology. 2000;107:1287–93. doi: 10.1016/S0161-6420(00)00138-X.
    1. Leske MC, Wu SY, Hennis A, Honkanen R, Nemesure B, BESs Study Group Risk factors for incident open-angle glaucoma: the Barbados Eye Studies. Ophthalmology. 2008;115:85–93. doi: 10.1016/j.ophtha.2007.03.017.
    1. De Moraes CG, Liebmann JM, Greenfield DS, Gardiner SK, Ritch R, Krupin T, et al. Risk factors for visual field progression in the low-pressure glaucoma treatment study. Am J Ophthalmol. 2012;154:702–11. doi: 10.1016/j.ajo.2012.04.015.
    1. Okumura Y, Yuki K, Tsubota K. Low diastolic blood pressure is associated with the progression of normal-tension glaucoma. Ophthalmologica. 2012;228:36–41. doi: 10.1159/000335978.
    1. Janulevičiene I, Ehrlich R, Siesky B, Nedzelskienė I, Harris A. Evaluation of hemodynamic parameters as predictors of glaucoma progression. J Ophthalmol. 2011;2011:164320.
    1. Ramdas WD, Wolfs RC, Hofman A, de Jong PT, Vingerling JR, Jansonius NM. Ocular perfusion pressure and the incidence of glaucoma: real effect or artifact? The Rotterdam Study. Invest Ophthalmol Vis Sci. 2011;52:6875–81. doi: 10.1167/iovs.11-7376.
    1. Khawaja AP, Crabb DP, Jansonius NM. The role of ocular perfusion pressure in glaucoma cannot Be studied with multivariable regression analysis applied to surrogates. Invest Ophthalmol Vis Sci. 2013;54:4619–20. doi: 10.1167/iovs.13-12487.
    1. Mosaed S, Liu JH, Weinreb RN. Correlation between office and peak nocturnal intraocular pressures in healthy subjects and glaucoma patients. Am J Ophthalmol. 2005;139:320–4. doi: 10.1016/j.ajo.2004.09.062.
    1. Fogagnolo P, Orzalesi N, Ferreras A, Rossetti L. The circadian curve of intraocular pressure: can we estimate its characteristics during office hours? Invest Ophthalmol Vis Sci. 2009;50:2209–15. doi: 10.1167/iovs.08-2889.
    1. Quaranta L, Katsanos A, Russo A, Riva I. 24-hour intraocular pressure and ocular perfusion pressure in glaucoma. Surv Ophthalmol. 2013;58:26–41. doi: 10.1016/j.survophthal.2012.05.003.
    1. Quaranta L, Konstas AG, Rossetti L, Garcia-Feijoo J, O'Brien C, Nasr MB, et al. Untreated 24-h intraocular pressures measured with Goldmann applanation tonometry vs nighttime supine pressures with Perkins applanation tonometry. Eye (Lond) 2010;24:1252–8. doi: 10.1038/eye.2009.300.
    1. Konstas AG, Quaranta L, Mikropoulos DG, Nasr MB, Russo A, Jaffee HA, et al. Peak intraocular pressure and glaucomatous progression in primary open-angle glaucoma. J Ocul Pharmacol Ther. 2012;28:26–32. doi: 10.1089/jop.2011.0081.
    1. van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005;112:1177–85. doi: 10.1016/j.ophtha.2005.01.042.
    1. Quaranta L, Gandolfo F, Turano R, Rovida F, Pizzolante T, Musig A, et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci. 2006;47:2917–23. doi: 10.1167/iovs.05-1253.
    1. Orzalesi N, Rossetti L, Bottoli A, Fogagnolo P. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology. 2006;113:239–46. doi: 10.1016/j.ophtha.2005.10.045.
    1. Rossetti L, Karabatsas CH, Topouzis F, Vetrugno M, Centofanti M, Boehm A, et al. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure. Ophthalmology. 2007;114:2244–51. doi: 10.1016/j.ophtha.2007.01.025.
    1. Quaranta L, Katsanos A, Floriani I, Riva I, Russo A, Konstas AG. Circadian intraocular pressure and blood pressure reduction with timolol 0.5% solution and timogel 0.1% in patients with primary open-angle glaucoma. J Clin Pharmacol. 2012;52:1552–7. doi: 10.1177/0091270011420254.
    1. Januleviciene I, Siaudvytyte L, Diliene V, Barsauskaite R, Paulaviciute-Baikstiene D, Siesky B, et al. Comparison of intraocular pressure, blood pressure, ocular perfusion pressure and blood flow fluctuations during dorzolamide versus timolol add-on therapy in prostaglandin analogue treated glaucoma subjects. Pharmaceuticals. 2012;5:325–38. doi: 10.3390/ph5030325.
    1. Feke GT, Rhee DJ, Turalba AV, Pasquale LR. Effects of dorzolamide-timolol and brimonidine-timolol on retinal vascular autoregulation and ocular perfusion pressure in primary open angle glaucoma. J Ocul Pharmacol Ther. 2013;29:639–45. doi: 10.1089/jop.2012.0271.
    1. Costa VP, Jimenez-Roman J, Carrasco FG, Lupinacci A, Harris A. Twenty-four-hour ocular perfusion pressure in primary open-angle glaucoma. Br J Ophthalmol. 2010;94:1291–4. doi: 10.1136/bjo.2009.167569.
    1. Cherecheanu AP, Garhofer G, Schmidl D, Werkmeister R, Schmetterer L. Ocular perfusion pressure and ocular blood flow in glaucoma. Curr Opin Pharmacol. 2013;13:36–42. doi: 10.1016/j.coph.2012.09.003.
    1. Leske MC, Wu SY, Hennis A, Honkanen R, Nemesure B. Risk factors for incident open-angle glaucoma: the Barbados Eye Studies. Ophthalmology. 2008;115:85–93. doi: 10.1016/j.ophtha.2007.03.017.
    1. Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Snyder R. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol. 2001;119:1819–26. doi: 10.1001/archopht.119.12.1819.
    1. Topouzis F, Wilson MR, Harris A, Founti P, Yu F, Anastasopoulos E, et al. Association of open-angle glaucoma with perfusion pressure status in the Thessaloniki Eye Study. Am J Ophthalmol. 2013;155:843–51. doi: 10.1016/j.ajo.2012.12.007.
    1. Diestelhorst M, Larsson LI, European Latanoprost Fixed Combination Study Group A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br J Ophthalmol. 2004;88:199–203. doi: 10.1136/bjo.2003.018234.
    1. Diestelhorst M, Larsson LI, European-Canadian Latanoprost Fixed Combination Study Group A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology. 2006;113:70–6. doi: 10.1016/j.ophtha.2005.06.027.
Pre-publication history
    1. The pre-publication history for this paper can be accessed here:

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться